Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Dupixent Market Report 2025 The Business Research Company's Global Dupixent Market Outlook 2025-2034: Growth Drivers, Share, And Trends ...

His nasal congestion and postnasal drip improved and he was continued on Dupilumab. Variety of biological ... and patients tend to have more sinus disease. Monoclonal antibody therapies or ...

Interaction between OX40-L and its binding partner OX40 have been shown to play a central role in several inflammatory and autoimmune diseases. Sanofi and Regeneron’s Dupixent (dupilumab ...

Clinical trials with Dupilumab have shown that these cytokines are key drivers of multiple type 2 inflammatory diseases. Its use is approved in the United States, the European Union, and other ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.